Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jul 26, 2012 (14 years ago)

Ventolin HFA (Albuterol Sulfate)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Does Not Deliver Proper Metered Dose: Potential content of albuterol per dose is below specification.

Cause type: Other

Recalls whose stated reason does not fall into the categories above. See the recall's own reason text for the specifics. All other recalls.

What was recalled

Ventolin HFA (albuterol sulfate) Inhalation Aerosol 90 mcg per actuation, 200 Metered Inhalations, FOR ORAL INHALATION ONLY - For use with Ventolin HFA actuator only. Net. wt. 18 g Rx only, GlaxoSmithKline, Reasearch Triangle Park, NC 27709 NDC 0173-0682-20

Affected NDC 0173-0682-20

Compare with the code on your package — it is the most precise check available.

Drug: Albuterol

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Ventolin Hfa
albuterol sulfate
NDC 00173-0682
90 ug/1 Aerosol, Metered
Respiratory (inhalation)
GlaxoSmithKline LLC Rx
Recalling firm
GlaxoSmithKline Inc
NDC code
0173-0682-20
Origin
NC, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1666-2012 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Albuterol recalls

See all
Class III · Low risk

Albuterol Sulfate

Failed Stability Specifications: Out of specification results was observed in Induction Port during the analysis of Particle size distribution at the 12-month time point.

Ongoing Stability / shelf life Cipla USA, Inc. NDC 69097-142-60 D-0593-2025
Class I · High risk

Albuterol Sulfate Inhalation Aerosol

Defective container: empty inhaler and leakage observed through the inhaler valve due to partially missing bottom seat (gasket).

Terminated Packaging defect Cipla USA, Inc. NDC 69097-142-60 D-0938-2023

Other recalls by GlaxoSmithKline Inc

All 2012 recalls
Class III · Low risk

Tivicay PD

Labeling: Incorrect Lot and/or Expiration Date: The carton has incorrect expiration of 2026-MAY*, whereas the correct expiration date, which is on the tablet bottle label, is 2025-APR.

Terminated Labeling / mix-up GlaxoSmithKline LLC NDC 49702-255-37 D-0544-2024
Class III · Low risk

Anoro Ellipta

Failed Release Testing: Coarse Particle Mass for umeclidinium Out of Specification

Terminated Failed specification GlaxoSmithKline LLC NDC 0173-0869-10 D-0160-2024
Class III · Low risk

Tivicay (dolutegravir)

Labeling: incorrect or missing lot and/or expiration date. An incorrect expiration date was printed on the product labeling with an expiration date of January 2027, whereas the correct expiration date is September 2026.

Terminated Labeling / mix-up GlaxoSmithKline LLC NDC 49702-228-13 D-0896-2022
Class II · Moderate risk

Ventolin HFA

Defective Delivery System: Elevated number of units with out of specification results for leak rate

Ongoing Packaging defect GlaxoSmithKline, LLC NDC 0173-0682-20 D-0793-2017